CTSF and non-small cell lung carcinoma: A qualitative proteomics study by Wei et al. in 2022 [29] identified elevated levels of CTSF and other candidate proteins, including fibulin-1, in brain metastatic lesions from non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) compared to NSCLC tissues without BMs and primary brain tumor samples.